In the study, OncoScreen Plus was used to determine activating mutations in PIK3CA and AKT1 and inactivating alterations in PTEN genes for patients in the trial who were enrolled in China.

Results of the study were published in the New England Journal of Medicine on June 1.

The study, CAPItello-291, aimed to assess the safety and efficacy of capivasertib–fulvestrant combination therapy in a cohort of 708 advanced breast cancer patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) cancer whose disease had progressed during or after aromatase inhibitor therapy.

The study findings showed that capivasertib–fulvestrant combination therapy resulted in significantly longer progression-free survival than treatment with fulvestrant alone.

The study was funded by AstraZeneca and the National Cancer Institute.

Immune system B-cells help predict breast cancer treatment response
UNC Lineberger Comprehensive Cancer Center researchers have found that measuring immune system B-cell activation may be better at predicting HER2-positive...

Immune conversion of cancer cells sensitizes them to immunotherapy
Researchers at the University of Texas MD Anderson Cancer Center have developed a nanotechnology platform that changes the immune system's perception...

Tvardi’s TTI-101 overcomes palbociclib resistance in breast cancer models
Tvardi Therapeutics will present preclinical data on April 11 at the 2022 Annual Meeting of the American Association for Cancer Research in New Orleans....

Scientists identify diagnostic gene signature for breast cancer
Researchers have identified a diagnostic signature for genetic mutations and other abnormalities associated with drug resistance and poor outcomes in...